Fluorides: Getting the benefits, avoiding the risks

Food Insecurity and the Dangers of Infant Formula Dilution

In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).

January 30th 2023

Addictive screen use tied to youth mental health risks

Morgan Ebert, Managing Editor

Demystifying Infant Formula

Addictive use of screens—not total time—was linked to higher risks of suicidal behavior and mental health issues in early adolescents.

October 11th 2022

FDA approves twice-yearly lenacapavir as PrEP for HIV in adolescents, adults

FDA approves lenacapavir as PrEP for HIV in adults, adolescents weighing at least 35 kg | Image Credit: Contemporary Pediatrics

Joshua Fitch, Senior Editor

June 18th 2025

Olivia is helping patients and families understand the experience of blood cancer

Lenacapavir is the first twice-yearly option available in the US for those who need or want PrEP, according to Gilead Sciences.

The Leukemia & Lymphoma Society

June 18th 2025

Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD

Related Content

Michael O. Daines, MD

Food Insecurity and the Dangers of Infant Formula Dilution

In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).

January 30th 2023

Addictive screen use tied to youth mental health risks

Morgan Ebert, Managing Editor

Demystifying Infant Formula

Addictive use of screens—not total time—was linked to higher risks of suicidal behavior and mental health issues in early adolescents.

October 11th 2022